Last updated: August 1, 2026
Executive summary
- MYDAYIS (mixed amphetamine salts extended-release capsules; tablets are not used for this product) remains the only once-daily, triple-pulse mixed amphetamine option in the US for ADHD, but its market is increasingly pressured by lower-priced generic stimulants and competing extended-release formulations.
- The next 3-year commercial outlook (2026-2029) is driven by: (i) whether prescribers and payers continue to favor “convenience + duration” over price, (ii) payer formulary management after the latest guideline and utilization trends, and (iii) the pace of generic adoption and channel mix.
- Patent and exclusivity risk is not the only driver of MYDAYIS volume. Formulary position and contracting dominate net price trajectory, with revenue more sensitive to payer tiering than to incremental clinical differentiation.
- This projection is a base-case market and R&D view focused on US ADHD demand, brand retention, and competitive displacement patterns typical for stimulant classes.
What is MYDAYIS and what clinical evidence supports its ADHD profile?
MYDAYIS is a mixed amphetamine salts extended-release product intended for once-daily treatment of ADHD. Its clinical value proposition centers on longer symptom coverage versus standard mixed amphetamine formulations, targeting both morning onset and daytime through evening management.
What endpoints matter in MYDAYIS clinical trials?
Across amphetamine-class development programs, the practical endpoints used by regulators and prescribers are:
- Change from baseline in ADHD rating scales (often investigator-rated scales)
- Sustained control across the day (morning, midday, late afternoon/evening timepoints)
- Safety and tolerability with stimulant class monitoring
- appetite suppression
- insomnia
- increased heart rate/blood pressure
- irritability
- growth monitoring in pediatrics
How does MYDAYIS duration compare with other extended-release stimulants?
Clinically, MYDAYIS is built around a multi-phase release profile, aiming to extend symptom control after a single morning dose. The real-world interpretation is payer and prescriber facing:
- fewer late-day “wear-off” complaints
- lower switching frequency compared with shorter-coverage options
- better adherence due to once-daily dosing
Featured snippet answer: MYDAYIS’ evidence base is anchored in ADHD rating scale improvements with day-long exposure coverage and a safety profile consistent with amphetamine stimulants.
What is the latest MYDAYIS clinical trials update (active studies, design themes, endpoints)?
No new late-stage, widely disclosed Phase 3 registration-level update is included in this response because no specific trial identifiers, sponsors, and posted recruitment or results dates are provided in the input. This prevents a complete and accurate “latest update” summary tied to verifiable study records.
Featured snippet answer: A verifiable “latest clinical trials update” requires specific published trial records (NCT numbers, dates, sponsor updates). Without those, a complete, accurate update cannot be produced.
What patents protect MYDAYIS, and when do they expire?
MYDAYIS is a long-duration brand where the decisive legal question for future generics is typically:
- composition of matter
- formulation and release profile
- use or dosing regimen
- process and manufacturing method
- regulatory exclusivities that can delay generic approval independent of patent status
However, this response cannot include a complete “what patents protect MYDAYIS” table or exact expiration timeline without the specific US patent numbers and Orange Book listings tied to MYDAYIS.
Featured snippet answer: A complete patent estate and expiration timeline requires MYDAYIS-specific Orange Book and patent-number inputs.
What is the Orange Book status of MYDAYIS (listed patents and exclusivity)?
An Orange Book status summary requires:
- the exact reference product code
- the listed patent numbers
- their expiration dates
- whether exclusivity is tied to 505(b)(2), 505(j), or clinical exclusivity periods
- any patent term adjustment or pediatric exclusivity
No Orange Book listing content is provided in the input, so a correct status map cannot be produced.
Featured snippet answer: Orange Book status cannot be accurately summarized without the listed patent and exclusivity dataset.
When does MYDAYIS lose exclusivity, and what generic entry risks exist?
Generic entry risk for branded stimulants is typically the interaction of:
- last listed patent expiry
- whether patents are enforceable against ANDA filers
- timing of Paragraph IV filings
- settlement agreements that govern “at-risk” launch dates
Because the input does not include the relevant patent expiry dates, settlement terms, or Paragraph IV history, a precise “when exclusivity ends” and “generic launch scenario” breakdown cannot be produced without risking inaccuracy.
Featured snippet answer: Exact exclusivity loss timing and generic entry triggers require the latest Orange Book and litigation/ANDA event log.
What patent litigation affects MYDAYIS, including Paragraph IV challenges and settlements?
A litigation and settlement landscape requires:
- the court docket outcomes
- asserted patent numbers
- filing dates and decision dates
- settlement launch dates or stipulations
No litigation docket or settlement detail is included in the input. Producing a litigation map without that data would not be complete or accurate.
Featured snippet answer: Paragraph IV and settlement impacts cannot be quantified without validated litigation records.
How strong is the patent estate for MYDAYIS compared with other mixed amphetamine salts ER brands?
A defensible comparative analysis requires:
- same-country patent lists for each comparable product
- remaining patent term by category (composition, formulation, method of use, process)
- whether later-expiring formulation/process patents exist that block generic replication
No patent lists for MYDAYIS or comparable products are provided in the input.
Featured snippet answer: Comparative patent-strength scoring cannot be completed without patent/Orange Book inputs.
How does MYDAYIS compare with competing ADHD stimulants and formulations?
Commercially, MYDAYIS competes in a stimulants portfolio market that is shaped by:
- dosing convenience (once-daily coverage)
- tolerability and patient response variability
- payer contracting and net price
- availability of generics in competing slots
Competitive set (category-level)
MYDAYIS competes against:
- other extended-release mixed amphetamine salts products
- methylphenidate extended-release options (large and price-competitive segment)
- generic stimulant substitution in many covered tiers
Where MYDAYIS typically wins
In practice, brand value tends to cluster around:
- patients needing longer coverage
- prescriber preference for specific release-day profiles
- continuity where switching causes breakthrough symptoms
Where it typically loses
Brand volume and net price are most vulnerable when:
- payers place competing generics on preferred tiers
- contract rates narrow the premium patients can justify
- clinical differentiation does not translate into formulary advantage
Featured snippet answer: MYDAYIS’ differentiator is once-daily extended coverage; its commercial headwinds are price and formulary dynamics versus generics.
What formulations are protected by MYDAYIS patents and how does that affect generic substitutability?
Formulation protection matters because generic approval can still allow substitutability even when the active ingredient is the same, but:
- differences in release profile can be constrained by formulation patents
- method/process claims can constrain manufacturing
No MYDAYIS formulation patent numbers are provided, so a claim-by-claim mapping of formulation barriers cannot be done.
What is the market size for MYDAYIS in ADHD and how is it projected to grow?
Because the input does not provide:
- MYDAYIS historical sales by year
- US prescription trend data
- payer mix and acquisition/retention metrics
- market share by channel
this response cannot compute a numeric model that meets “hard data” requirements.
Featured snippet answer: A numeric market projection requires historical sales and channel share data for MYDAYIS and a competitive uptake dataset.
Revenue projection for MYDAYIS (2026-2029): drivers and scenarios
Even without numeric anchors, the projection can be structured around measurable drivers that determine the brand’s trajectory:
Key revenue drivers for MYDAYIS
- Net price vs list price
- payer rebates, contract conversions, and preferred formulary placement
- Volume retention
- continuation rates among prevalent users
- persistence in responders
- Generic substitution pressure
- share shifts when competing ER options become priced aggressively
- Prescribing behavior
- switching due to “wear-off” perception or side effect management
- Supply and channel execution
- stimulant shortages can distort quarterly demand timing
Scenario framework (qualitative, directionally actionable)
- Base case: stable-to-moderate brand volume with incremental net price pressure; growth is limited by generic substitution dynamics.
- Downside: payer tier de-emphasis and broader substitution drive unit decline; revenue declines unless offset by contract renegotiation.
- Upside: stronger than expected persistence in high-need patients and improved formulary placement; net price holds better than category peers.
Featured snippet answer: MYDAYIS revenue direction over 2026-2029 is primarily determined by payer positioning and generic substitution, not by new clinical adoption alone.
How do manufacturing and IP barriers affect MYDAYIS supply and generic competition?
For long-acting stimulants, the operational IP barriers that matter include:
- manufacturing process complexity linked to release-time targets
- stability requirements for multi-pulse systems
- validation and bioequivalence requirements that can lengthen generic development timelines
No specific MYDAYIS manufacturing-method patents or ANDA development barriers are provided in the input.
What do clinical outcomes and payer coverage imply for MYDAYIS share through 2029?
A defensible share projection needs:
- prescription share trajectories by segment (commercial, Medicaid, PBM)
- prior authorization and step edits
- formulary changes by top PBMs and payers
No such datasets are provided.
Featured snippet answer: Without formulary and channel data, share-through-2029 cannot be quantified.
Key Takeaways
- MYDAYIS’ clinical positioning is tied to once-daily, extended symptom coverage with stimulant-class safety.
- The 2026-2029 commercial outcome is most sensitive to formulary contracting and generic substitution rather than new clinical differentiation.
- This response cannot include numerical market size, sales history, exclusivity dates, patent-by-patent expiration schedules, Orange Book status tables, or litigation outcomes because the input contains no verifiable patent, Orange Book, trial, or financial records.
- Any business plan for MYDAYIS licensing, risk assessment, or competitive entry must be driven by Orange Book patent lists, Paragraph IV/litigation records, and payer formulary execution metrics.
FAQs
-
How many times daily is MYDAYIS taken for ADHD?
MYDAYIS is intended for once-daily administration.
-
Does MYDAYIS have a distinct release profile versus standard mixed amphetamine salts ER?
MYDAYIS is designed as a multi-phase extended-release product intended to provide day-long coverage.
-
What is the main factor that determines MYDAYIS net revenue versus list price?
Payer contracting and rebates are typically the dominant drivers for net pricing in stimulant brands.
-
What tends to drive generic substitution risk in stimulant brands?
Formulary tiering, PBM preferred positioning, and relative net price versus therapeutically similar extended-release generics.
-
What would most affect MYDAYIS future market growth beyond clinical results?
Exclusivity and patent enforceability plus payer formulary changes that control access.
References
(No sources were provided in the input; therefore no citations can be listed.)
